K. Gordon, “Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials”, J of Skin, vol. 8, no. 4, p. s404, Jul. 2024.